Phaseline

Targets › BZLF1

BZLF1: drug programs, companies and trials

2 programs from 2 companies in 4 trials: 4 Phase 1; Infectious disease, Genitourinary; next expected readout May 2027.

Open in Phaseline: the race on BZLF1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ModernaTXmRNA-1189
mRNA vaccine encoding Epstein-Barr virus antigens
EBNA1, LMP1, BZLF1Phase 1Epstein-Barr Virus Infection; Epstein-Barr VirusMay 2027
Ohio State University Comprehensive Cancer CenterOSU-2131
BZLF1 peptide vaccine (rh-Hsc70-BZLF1 peptide complex)
BZLF1Phase 1Chronic Kidney Disease, Stage 4Jul 2027

Conditions

Epstein-Barr Virus Infection (2) Epstein-Barr Virus (1) Chronic Kidney Disease, Stage 4 (1)

Modalities

other (1), mixed (1)

Companies

ModernaTX (1) Ohio State University Comprehensive Cancer Center (1)

Related targets

EBNA1 (1) LMP1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.